UNIVERSITATEA “TRANSILVANIA” BRASOV

3.6 Basic conditions and development tendencies around the globe ···········································26
3.7 Conclusion concerning distribution challenges in Europe ·····················································26
CHAPTER 4 - NEW CONCEPTS WITHIN......................................................................................
PHARMACEUTICAL MARKETING........................................................................................... 27
4.1 Pharmaceutical marketing mix···································································································27
4.2 New concepts in pharmaceutical marketing ·············································································28
4.3 Social Marketing····························································································································28
4.4 Integrated Customer Marketing·································································································29
4.5 Limited product opportunities in pharmaceuticals·································································30
CHAPTER 5 - NEW DISTRIBUTION MODELS.............................................................................
WITHIN PHARMACEUTICALS.................................................................................................. 31
5.1 Cost evaluation as the base for new distribution models ························································31
5.2 Increasing control of drug distribution to enhance patient safety ………………………33
CHAPTER 6 - MARKETING RESEARCHES CHARACTERIZING THE DISTRIBUTION
WITHIN THE PHARMACEUTICAL MARKET.............................................................................
IN GERMANY ................................................................................................................................ 33
6.1 Questionnaire conception·············································································································33
6.2 Evaluation and interpretation·····································································································34
6.2.1 System changes and cost reductions implications ........................................................ 34
6.2.2 Openness for changes in the distribution cycle in the enterprises............................... 34
6.2.3 How high are the following cost factors being rated? .................................................. 34
6.2.4 Physical structure and controlling of the supply chain................................................ 35
6.2.5 Equipment of the national and/or European central storage depots .......................... 35
6.2.6 Trends in the outsourcing process ................................................................................ 36
6.2.7 Supply chain co-operations ........................................................................................... 36
6.3 Expectations and openness for new models in the pharmaceutical sector···························36
6.4 Key results of empirical study·····································································································37
6.5 Interpretation of the key trends – based on the findings of the empirical study ················38
CONCLUSIONS AND PERSONAL CONTRIBUTIONS............................................................. 39
ILLUSTRATIONS OVERVIEW ................................................................................................... 41
LITERATURE OVERVIEW ......................................................................................................... 43
INTRODUCERE............................................................................................................................... 8
CAPITOLUL 1 – PIAŢA FARMACEUTICĂ ................................................................................. 8
1.1 Creşterea costurilor de sănătate în lume .···············································································8
1.1.1 Costurile în sănătate reprezintă o serioasă problemă de afaceri .......................................... 9
1.1.2 Stimulente Opt-Out .......................................................................................................... 9
1.1.3 Managementul performanţei furnizorului .......................................................................... 9
1.1.4 Opţiuni de management al bolii ........................................................................................ 9
1.2 Analiza pieţei farmaceutice ···········································································································10
1.2.1 Arii terapeutice majore ................................................................................................... 10
1.2.2 Zece companii domină piaţa farmaceutică din toată lumea ............................................. 10
1.2.3 Piaţa Statelor Unite, ca piaţa cea mai lucrativă ................................................................ 10
6